当前位置： SCI文献检索 > ONCOGENE期刊下所有文献 > Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis.

Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis.

Abstract：

:Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a glycoprotein that is part of the carcinoembryonic antigen and the immunoglobulin superfamilies. We have shown that it functions as a tumor suppressor and that this function depends upon the presence of the longer CEACAM1 cytoplasmic domain. In this report, we describe the generation of a Ceacam1-/- mouse. The Ceacam1-/- colon exhibits increased in vivo proliferation relative to the wild-type counterpart with a corresponding decreased expression of the p21(Cip1) and p27(Kip1) Cyclin D kinase inhibitors. The colonic villi undergo decreased apoptosis. Out of 35 litters of mice, no spontaneous tumors in any tissues normally expressing CEACAM1 were found over the lifespan of the animals, suggesting that CEACAM1 may not be involved in initiation of tumor development. However, when mice are treated with azoxymethane to induce colonic tumors, we find that Ceacam1-/- mice developed a significantly greater number of tumors than their littermate controls. Moreover, the tumor size was greater in the knockout mice relative to that in the wild-type mice. These results indicate that deletion of CEACAM1 favors progression of colon tumorigenesis.

journal_name

Oncogene

journal_title

Oncogene

authors

Leung N,Turbide C,Olson M,Marcus V,Jothy S,Beauchemin N

doi

10.1038/sj.onc.1209541

subject

Has Abstract

pub_date

2006-09-07 00:00:00

pages

5527-36

issue

40

eissn

0950-9232

issn

1476-5594

pii

1209541

journal_volume

25

pub_type

杂志文章

相关文献

ONCOGENE文献大全
  • Fibroblast growth factor receptor-1 mediates chemotaxis independently of direct SH2-domain protein binding.

    abstract：:Endothelial cells expressing fibroblast growth factor receptor-1 (FGFR-1) migrate and proliferate in response to treatment with FGF. We analysed ligand-induced migration and proliferation of porcine aortic endothelial cells expressing wild-type FGFR-1, point-mutated Y766F FGFR-1, unable to activate phospholipase C-gam...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1201936

    authors： Landgren E,Klint P,Yokote K,Claesson-Welsh L

    更新日期：1998-07-23 00:00:00

  • Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells.

    abstract：:Ret is a receptor tyrosine kinase predominantly expressed in tissue derived from the neuroectoderm and is involved in multiple endocrine neoplasia type 2A and 2B, familiar medullary thyroid carcinoma, and Hirschsprung's disease. The ligand for the receptor is still unknown. Previously, using a human epidermal growth f...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：

    authors： van Weering DH,Medema JP,van Puijenbroek A,Burgering BM,Baas PD,Bos JL

    更新日期：1995-12-07 00:00:00

  • The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity.

    abstract：:ERM is a member of the ETS transcription factor family. High levels of the corresponding mRNA are detected in a variety of human breast cancer cell lines, as well as in aggressive human breast tumors. As ERM protein is almost undetectable in these cells, high degradation of this transcription factor has been postulate...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1209801

    authors： Baert JL,Beaudoin C,Monte D,Degerny C,Mauen S,de Launoit Y

    更新日期：2007-01-18 00:00:00

  • Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene.

    abstract：:Somatic RET mutations have been identified in a variable proportion (about 30-70%) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1201079

    authors： Ceccherini I,Pasini B,Pacini F,Gullo M,Bongarzone I,Romei C,Santamaria G,Matera I,Mondellini P,Scopsi L,Pinchera A,Pierotti MA,Romeo G

    更新日期：1997-05-29 00:00:00

  • HUS1 regulates in vivo responses to genotoxic chemotherapies.

    abstract：:Cells are under constant attack from genotoxins and rely on a multifaceted DNA damage response (DDR) network to maintain genomic integrity. Central to the DDR are the ATM and ATR kinases, which respond primarily to double-strand DNA breaks (DSBs) and replication stress, respectively. Optimal ATR signaling requires the...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/onc.2015.118

    authors： Balmus G,Lim PX,Oswald A,Hume KR,Cassano A,Pierre J,Hill A,Huang W,August A,Stokol T,Southard T,Weiss RS

    更新日期：2016-02-04 00:00:00

  • Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.

    abstract：:Targeted therapeutics, such as those abrogating hypoxia inducible factor (HIF)/vascular endothelial growth factor signaling, are initially effective against kidney cancer (or renal cell carcinoma, RCC); however, drug resistance frequently occurs via subsequent activation of alternative pathways. Through genome-scale i...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/onc.2016.510

    authors： Chen CH,Fong LWR,Yu E,Wu R,Trott JF,Weiss RH

    更新日期：2017-06-22 00:00:00

  • A pancreatic cancer-specific expression profile.

    abstract：:We present an approach making use of technology established in the context of the genome project to describe a pancreatic cancer-specific expression profile and to identify new potential disease genes or disease-associated-genes. By use of gridded arrays of pancreatic cancer cDNA libraries and differential hybridizati...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：

    authors： Gress TM,Müller-Pillasch F,Geng M,Zimmerhackl F,Zehetner G,Friess H,Büchler M,Adler G,Lehrach H

    更新日期：1996-10-17 00:00:00

  • Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells.

    abstract：:Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy because of its relative tumor selectivity. However, many cancers including pancreatic cancer remain resistant towards TRAIL. To develop TRAIL for cancer therapy of pancreatic carcinoma, it will therefore b...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1209776

    authors： Vogler M,Dürr K,Jovanovic M,Debatin KM,Fulda S

    更新日期：2007-01-11 00:00:00

  • Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b.

    abstract：:The Ets transcription factor PU.1 is a hematopoietic master regulator essential for the development of myeloid and B-cell lineages. As we previously reported, PU.1 sometimes represses transcription on forming a complex with mSin3A-histone deacetyl transferase-MeCP2. Here, we show an interaction between PU.1 and DNA me...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1209272

    authors： Suzuki M,Yamada T,Kihara-Negishi F,Sakurai T,Hara E,Tenen DG,Hozumi N,Oikawa T

    更新日期：2006-04-20 00:00:00

  • Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers.

    abstract：:Loss of heterozygosity on chromosome 10p was observed frequently in human prostate cancers. Studies have demonstrated that the introduction of the short arm of human chromosome 10 into a human prostate cancer cell line, PPC-1, by microcell-mediated chromosome transfer (MMCT), suppressed the malignant phenotype, sugges...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1204079

    authors： Fukuhara H,Maruyama T,Nomura S,Oshimura M,Kitamura T,Sekiya T,Murakami Y

    更新日期：2001-01-18 00:00:00

  • ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3.

    abstract：:Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer and frequently diagnosed at an advanced stage. It is prone to develop unpredictable metastases even with proper treatment. Antiangiogenic therapy is the most effective medical treatment for metastatic ccRCC. Thus, exploration of novel approaches t...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/s41388-020-01428-3

    authors： Li YL,Wu LW,Zeng LH,Zhang ZY,Wang W,Zhang C,Lin NM

    更新日期：2020-09-01 00:00:00

  • Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells.

    abstract：:Although Kruppel-like factor 5 (KLF5) is a transcription factor that has been implicated in pathways critical to carcinogenesis, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. Here, we describe a novel role for KLF5 in a p53-independent apoptotic pathway. Using RNA-interferenc...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1210625

    authors： Zhao Y,Hamza MS,Leong HS,Lim CB,Pan YF,Cheung E,Soo KC,Iyer NG

    更新日期：2008-01-03 00:00:00

  • The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer.

    abstract：:Epithelial-mesenchymal transition (EMT) facilitates cancer invasion and metastasis and thus accelerates cancer progression. p21-activated kinase 4 (PAK4) is a critical regulator of prostate cancer (PC) progression. Here, we report that PAK4 activation promotes PC progression through the EMT regulator Slug. We find tha...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/s41388-018-0327-8

    authors： Park JJ,Park MH,Oh EH,Soung NK,Lee SJ,Jung JK,Lee OJ,Yun SJ,Kim WJ,Shin EY,Kim EG

    更新日期：2018-09-01 00:00:00

  • Identification of novel VHL targets that are associated with the development of renal cell carcinoma.

    abstract：:von Hippel-Lindau (VHL) disease is a dominantly inherited family cancer syndrome characterized by the development of retinal and central nervous system haemangioblastomas, renal cell carcinoma (RCC) and phaeochromocytoma. Specific germline VHL mutations may predispose to haemangioblastomas, RCC and phaeochromocytoma t...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1209932

    authors： Abdulrahman M,Maina EN,Morris MR,Zatyka M,Raval RR,Banks RE,Wiesener MS,Richards FM,Johnson CM,Latif F,Maher ER

    更新日期：2007-03-08 00:00:00

  • GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring.

    abstract：:GRIM-19 (Gene associated with Retinoid-Interferon-induced Mortality 19) is a novel tumor suppressor regulated by interferon/retinoid combination. We have recently shown that GRIM-19 inhibits v-Src-induced oncogenic transformation and metastatic behavior of cells. Oncogenic v-Src induces cell motility by cytoskeletal r...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/onc.2008.480

    authors： Sun P,Nallar SC,Kalakonda S,Lindner DJ,Martin SS,Kalvakolanu DV

    更新日期：2009-03-12 00:00:00

  • Vimentin is a novel AKT1 target mediating motility and invasion.

    abstract：:The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a ...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/onc.2010.421

    authors： Zhu QS,Rosenblatt K,Huang KL,Lahat G,Brobey R,Bolshakov S,Nguyen T,Ding Z,Belousov R,Bill K,Luo X,Lazar A,Dicker A,Mills GB,Hung MC,Lev D

    更新日期：2011-01-27 00:00:00

  • Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.

    abstract：:The DNA-binding, transcriptional activation and transforming activities of the Myc protein require dimerization with Max. Max can form also homodimers which are able to bind the same DNA sequence as Myc/Max heterodimers and suppress Myc-induced transcription and transformation. We have recently identified a naturally ...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：

    authors： Västrik I,Mäkelä TP,Koskinen PJ,Alitalo K

    更新日期：1995-08-03 00:00:00

  • Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.

    abstract：:Ovarian cancer is currently the second leading cause of gynecological malignancy and cisplatin or cisplatin-based regimens have been the standard of care for the treatment of advance epithelial ovarian cancers. However, the efficacy of cisplatin treatment is often limited by the development of drug resistance either t...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1209836

    authors： Leong CT,Ong CK,Tay SK,Huynh H

    更新日期：2007-02-08 00:00:00

  • Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia.

    abstract：:Murine radiation-induced acute myeloid leukaemia (AML) is characterized by loss of one copy of chromosome 2. Previously, we positioned the critical haematopoietic-specific transcription factor PU.1 within a minimally deleted region. We now report a high frequency (>65%) of missense mutation at codon 235 in the DNA-bin...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1208422

    authors： Suraweera N,Meijne E,Moody J,Carvajal-Carmona LG,Yoshida K,Pollard P,Fitzgibbon J,Riches A,van Laar T,Huiskamp R,Rowan A,Tomlinson IP,Silver A

    更新日期：2005-05-19 00:00:00

  • Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations.

    abstract：:The majority (75%) of human breast cancers express estrogen receptor (ER). Although ER-positive tumors usually respond to antiestrogen therapies, 30% of them do not. It is not known what controls the ER status of breast cancers or their responsiveness to antihormone interventions. In this report, we document that tran...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1208597

    authors： Zhang X,Podsypanina K,Huang S,Mohsin SK,Chamness GC,Hatsell S,Cowin P,Schiff R,Li Y

    更新日期：2005-06-16 00:00:00

  • Detection of novel mRNA splice variants of human ING4 tumor suppressor gene.

    abstract：:Inhibitor of growth (ING)4, member of a gene family encoding potential tumor suppressors, is implicated as a repressor of angiogenesis and tumor growth and suppresses loss of contact inhibition in vitro. Here, we report that ING4 undergoes alternative splicing. Expression analysis identified novel ING4 spliced variant...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1210335

    authors： Raho G,Miranda C,Tamborini E,Pierotti MA,Greco A

    更新日期：2007-08-09 00:00:00

  • TGF-beta1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate.

    abstract：:Cytokines can influence the interactions between members of the integrin cell adhesion receptor family and the extracellular matrix thereby potentially affecting cell function and promoting cell adhesion, growth and migration of malignant astrocytoma tumor cells. As malignant astrocytoma cells synthesize TGF-beta1 in ...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1204996

    authors： Han X,Stewart JE Jr,Bellis SL,Benveniste EN,Ding Q,Tachibana K,Grammer JR,Gladson CL

    更新日期：2001-11-29 00:00:00

  • The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers.

    abstract：:Disseminated breast cancer cells employ adaptive molecular responses following cytotoxic therapeutic insult which promotes their survival and subsequent outgrowth. Here we demonstrate that expression of the pro-metastatic lncRNA BORG (BMP/OP-Responsive Gene) is greatly induced within triple-negative breast cancer (TNB...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/s41388-018-0586-4

    authors： Gooding AJ,Zhang B,Gunawardane L,Beard A,Valadkhan S,Schiemann WP

    更新日期：2019-03-01 00:00:00

  • A functional link between the tumour suppressors ARF and p33ING1.

    abstract：:The ARF tumour suppressor protein plays a critical role in the activation of p53 in response to oncogenic stress. ARF can activate p53 through nucleolar sequestration of Mdm2. However, several lines of evidence indicate that this is not the only way of action of ARF, and alternative mechanisms must exist. p33ING1 is a...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1209526

    authors： González L,Freije JM,Cal S,López-Otín C,Serrano M,Palmero I

    更新日期：2006-08-24 00:00:00

  • MUC1-C activates BMI1 in human cancer cells.

    abstract：:B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is a component of the polycomb repressive complex 1 (PRC1) complex that is overexpressed in breast and other cancers, and promotes self-renewal of cancer stem-like cells. The oncogenic mucin 1 (MUC1) C-terminal (MUC1-C) subunit is similarly overex...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/onc.2016.439

    authors： Hiraki M,Maeda T,Bouillez A,Alam M,Tagde A,Hinohara K,Suzuki Y,Markert T,Miyo M,Komura K,Ahmad R,Rajabi H,Kufe D

    更新日期：2017-05-18 00:00:00

  • Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes.

    abstract：:Antioxidant response element (ARE)-mediated expression and coordinated induction of genes encoding detoxifying enzymes is one mechanism of critical importance to cellular protection against oxidative stress. In the present report, we demonstrate that nuclear transcription factors Nrf2 and Nrf1 associate with Jun (c-Ju...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1202237

    authors： Venugopal R,Jaiswal AK

    更新日期：1998-12-17 00:00:00

  • Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.

    abstract：:Smad4 is a critical component in transforming growth factor beta (TGF-beta) signaling and frequently mutated in pancreatic and colorectal cancers. Smad4 has two important functional domains, MH1 and MH2, that are involved in different biological processes. The MH1 domain comprises a DNA binding domain and the MH2 doma...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1207219

    authors： Kuang C,Chen Y

    更新日期：2004-02-05 00:00:00

  • Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation.

    abstract：:Silencing of gene expression by methylation of CpG islands in regulatory elements is frequently observed in cancer. However, an influence of the most common oncogenic signalling pathways onto DNA methylation has not yet been investigated thoroughly. To address this issue, we identified genes suppressed in HRAS-transfo...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/sj.onc.1209502

    authors： Lund P,Weisshaupt K,Mikeska T,Jammas D,Chen X,Kuban RJ,Ungethüm U,Krapfenbauer U,Herzel HP,Schäfer R,Walter J,Sers C

    更新日期：2006-08-10 00:00:00

  • Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1.

    abstract：:The metastasis-associated protein 1 (MTA1) is overexpressed in various human cancers and is closely connected with aggressive phenotypes; however, little is known about the transcriptional regulation of the MTA1 gene. This study identified the MTA1 gene as a target of p53-mediated transrepression. The MTA1 promoter co...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/onc.2012.2

    authors： Lee MH,Na H,Kim EJ,Lee HW,Lee MO

    更新日期：2012-12-06 00:00:00

  • FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.

    abstract：:Targeting Bruton tyrosine kinase (BTK) by ibrutinib is an effective treatment for patients with relapsed/refractory mantle cell lymphoma (MCL). However, both primary and acquired resistance to ibrutinib have developed in a significant number of these patients. A combinatory strategy targeting multiple oncogenic pathwa...

    journal_title：Oncogene

    pub_type： 杂志文章

    doi：10.1038/onc.2016.155

    authors： Li Y,Bouchlaka MN,Wolff J,Grindle KM,Lu L,Qian S,Zhong X,Pflum N,Jobin P,Kahl BS,Eickhoff JC,Wuerzberger-Davis SM,Miyamoto S,Thomas CJ,Yang DT,Capitini CM,Rui L

    更新日期：2016-12-01 00:00:00